DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, nothing will not stop me except God................DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 25Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK GENERICS at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution
Showing posts with label (5-Chloro-2-methoxyphenyl)[3-fluoro-5-(trifluoromethyl)phenyl]methanone. Show all posts
Showing posts with label (5-Chloro-2-methoxyphenyl)[3-fluoro-5-(trifluoromethyl)phenyl]methanone. Show all posts

Monday 13 February 2017

(5-Chloro-2-methoxyphenyl)[3-fluoro-5-(trifluoromethyl)phenyl]methanone

str1
Cas 329941-92-6
(5-Chloro-2-methoxyphenyl)[3-fluoro-5-(trifluoromethyl)phenyl]methanone (7)
7 as white crystals
 
mp 93–95 °C;
 
1H NMR (500 MHz, CDCl3) 7.82 (s, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.53 (d, J =7.5 Hz, 1H), 7.49 (d, J = 9.0 Hz, 1H), 7.42 (s, 1H), 6.97 (d, J = 9.0 Hz, 1H), 3.71 (s, 3H);
 
13C NMR (500 MHz, CDCl3) 192.1, 162.4 (d, J = 249.3 Hz), 156.0, 140.4 (d, J = 6.4 Hz), 132.8, 132.7 (dq, J = 7.5, 33.6 Hz), 129.7, 128.4, 126.3, 122.9 (q, J = 272.3), 122.1 (m), 119.5 (d, J = 22.4), 116.9 (m), 113.3, 55.3;
 
HRMS calculated for C15H9ClF4O2 [M + H]+: 333.0299, Found: 333.0306.
 
Abstract Image
A convergent synthesis of NNRTI 1 is described. The key step involves a direct coupling of acid chloride 4 with Grignard reagent 11 in the presence of bis[2-(N,N-dimethylamino)ethyl] ether that moderates the reactivity of the Grignard reagent to give benzophenone 7. An efficient 2-step process for the preparation of 2-fluoro-3-methyl-4-aminobenzoic acid (3) is also described.

Practical Synthesis of A Benzophenone-Based NNRT Inhibitor of HIV-1

 Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, United States
 Boehringer Ingelheim (Canada) Ltd., Research and Development, 2100 Cunard Street, Laval, Québec H7S 2G5, Canada
Org. Process Res. Dev.201216 (4), pp 561–566
DOI: 10.1021/op200301h
 
///////